PUBLIC HEALTH MODEL SYSTEM--BLOOD CHOLESTEROL SCREENING

马萨诸塞州公共卫生部提议实施一项 胆固醇筛查、教育和教育的公共卫生模式体系 转介。在四个不同种族，民族， 和社会经济人口，它将教育医生关于 中重度高血压患者救治的重要性和方法 并建立一个由愿意 接受这样的病人。 在进行社区分析以建立最合适的站点之后 进行筛选和最有效的招聘手段 志愿者将接受筛选，该部门将使用专门培训的团队 在每个国家开展其筛查、教育和转介计划 社区。大约11,000人将接受筛查 便携式再加速器分析仪。将抽取静脉穿刺物样本并 对十分之一的筛查对象进行分析，以验证可靠性 关于Refltron的决定。 筛查者将接受有关血清的教育和咨询 健康专业人士或训练有素的业馀人员提供的胆固醇和饮食 人。将与所提到的一半的人进行额外的联系 医生在两周内，看看这是否会增加发病率 成功的推荐人。将对所有个人进行跟踪 转介给医生以确定转介成功率和 开了什么治疗药方。对于那些被引用的子样本， 将在六个月内进行跟踪活动，以确定变化 饮食脂肪摄入量以及是否正在服用任何药物。 将对此子样本进行重复的Refltron血液样本采集，以查看 自最初筛查以来，血清胆固醇水平是否发生了变化。

The Massachusetts Department of Public Health proposes to implement a public health model system for cholesterol screening, education, and referral. Working in four communities with a diversity of racial, ethnic, and socioeconomic populations, it will educate physicians as to the importance and means of treating patients with moderate and high levels of serum cholesterol and establish a referral network of physicians willing to accept such patients. After conducting community analyses to establish the most appropriate sites for conducting screenings and the most effective means of recruiting volunteers to be screened, the Department will use a specially trained team to conduct its screening, education, and referral programs in each community. Approximately 11,000 individuals will be screened using a portable Reflotron analyzer. Venipuncture samples will be drawn and analyzed for one-tenth of those screened in order to verify the reliability of the Reflotron determinations. Those screened will receive education and counseling about serum cholesterol and diet by either a health professional or a trained lay person. Additional contact will be made with one-half of those referred to physicians within two weeks in order to see whether this increases the rate of successful referrals. Follow-up will be conducted on all individuals referred to physicians to determine the rate of successful referrals and what treatments have been prescribed. For a subsample of those referred, follow-up activities will be conducted at six months to ascertain changes in dietary fat consumption and whether any medications are being taken. Repeat Reflotron blood samples will be taken on this subsample to see whether serum cholesterol levels have changed since the initial screening.